SEATTLE


,

Jan. 5, 2023

/PRNewswire/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at the 41

^st

Annual J.P. Morgan Healthcare Conference in

San Francisco

.

Presentation details:

Event: 41

^st

Annual J.P. Morgan Healthcare Conference

Date:

Thursday, January 12

, 2023

Time:

7:30 a.m. PT

/

10:30 a.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at

www.ctibiopharma.com

.

About CTI BioPharma Corp.

We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO

^®

(pacritinib), a JAK2 and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10

⁹

/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO

^®

is a registered trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:


Argot Partners

+212-600-1902


[email protected]

View original content to download multimedia:

https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301713528.html

SOURCE CTI BioPharma Corp.